MedTrace Logo

Travoprost 3-Month Safety and Efficacy Study

NCT01453855 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1099

Last updated 2013-10-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to demonstrate that the intraocular pressure-lowering efficacy of Travoprost 0.003% is equivalent to TRAVATAN® in adult patients with open-angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

Travoprost ophthalmic solution, 0.003%

DRUG

Travoprost ophthalmic solution, 0.004%

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Theresa A Landry, PhD · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-08-31
Completion
2012-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01453855 on ClinicalTrials.gov